Thumbnail Image
Publication

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Thatcher, Nick
; 
Hirsch, F
; 
Luft, A
; 
Szczesna, A
; 
Ciuleanu, T
; 
Dediu, M
; 
Ramlau, R
; 
Galiulin, R
; 
Bálint, B
; 
Losonczy, G
... show 10 more
Citations
Altmetric:
Abstract
Necitumumab is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody. In this study, we aimed to compare treatment with necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients with previously untreated stage IV squamous non-small-cell lung cancer.
Authors
Thatcher, Nick
Hirsch, F
Luft, A
Szczesna, A
Ciuleanu, T
Dediu, M
Ramlau, R
Galiulin, R
Bálint, B
Losonczy, G
Kazarnowicz, A
Park, K
Schumann, C
Reck, M
Depenbrock, H
Nanda, S
Kruljac-Letunic, A
Kurek, R
Paz-Ares, L
Socinski, M
Affiliation
The Christie Hospital, Manchester, UK.
Description
Date
2015-07
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. 2015, 16 (7):763-74 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/560896
Embedded videos